New reports from pharmacy giant Janssen and Pharmaceutical Research and Manufacturers of America (PhRMA) suggest that the pharma sector could be making the 340B program an even bigger target than it has been in recent years.
Drug industry consulting and contract research firm IQVIA reports that prescription drug sales at 340B-discounted prices grew 18.1% year-on-year from 2019 to 2020.
340B hospitals provide “a significantly higher average number” of medication access (MA) services—such as free or discounted drugs or free delivery—than comparably sized non-340B hospitals, a new academic study shows. …
Please Login or Become a Paid
A study published online by Health Affairs yesterday focused on nonprofit hospitals’ provision of charity care could renew drug manufacturers’ calls for more control over those hospitals’ participation in the 340B program. …
Please Login or Become
340B hospitals are under significant pressure due to drug manufacturers ending 340B discounts on drugs dispensed by contract pharmacies, hospital advocacy group 340B Health says in its latest annual member survey. …
Please Login or Become a
Medicare Part B drug payments to 340B hospitals “declined substantially” in 2019 because the payment status of “an unusually high number of drugs” changed that year, congressional Medicare advisers said in a report yesterday. …
Please Login
More than 70 percent of U.S. spending on top-selling “partial orphan drugs”—drugs for rare diseases that also are approved to treat common diseases—is for non-orphan indications, a study in latest edition of Health Affairs concludes. Policymakers who “wish to decrease …
The ability to generate profits through the 340B program prompts hospitals to buy physician practices and shift delivery of care to more costly hospital outpatient settings, driving up drug costs for patients and employers, Pharmaceutical Research and Manufacturers of America …
Half (50 percent) of a sample of health care industry C-suite executives surveyed last month expect the Biden administration to “formally obligate drug manufacturers to offer 340B pricing,” consulting firm Advis reports in its first health care industry leadership survey …
28 State AGs—Including HHS Nominee Becerra—Want Action on Pharma 340B Pricing Denials. Also, New GAO Report on HRSA 340B Oversight. Twenty-eight state attorneys general—including California Attorney General Xavier Becerra (D), President-elect Biden’s nominee to be the next U.S. Health and …